Pediatrix Medical reports Q1 adjusted EPS 33c, consensus 24c

Reports Q1 revenue $458M, consensus $451.44M. “Our strong Q1 results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong Q1 performance, we are raising our full year 2025 Adjusted EBITDA outlook from a range of $215M-$235M to a range of $220M-$240M, demonstrating our commitment to delivering value for our stakeholders,” said Mark S. Ordan, CEO of Pediatrix Medical (MD) Group. “While we are raising our guidance, we remain mindful of the uncertainty that we face in the healthcare industry and the broad economic turbulence that is challenging virtually all companies.”